REGULUS THERAPEUTICS INC (RGLS) Stock Price, Quote, News and Overview
NASDAQ:RGLS - Nasdaq - US75915K3095 - Common Stock - Currency: USD
RGLS Quote, Performance and Key Statistics
1.35
+0.07 (+5.47%)
The current stock price of RGLS is 1.35 USD. In the past month the price increased by 35%. In the past year, price decreased by -9.4%.
RGLS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.66 | 369.39B | ||
| AMGN | AMGEN INC | 15.54 | 165.43B | ||
| GILD | GILEAD SCIENCES INC | 24.8 | 142.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1654.45 | 123.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.31 | 76.39B | ||
| ARGX | ARGENX SE - ADR | 242.12 | 37.96B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 29.00B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.07B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| BIIB | BIOGEN INC | 8.53 | 20.47B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.26B |
Related stock screener links
About RGLS
Company Profile
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2012-10-04. The firm is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The firm is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Company Info
REGULUS THERAPEUTICS INC
4224 Campus Point Court, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Joseph P. Hagan
Employees: 31
Company Website: https://www.regulusrx.com/
Investor Relations: http://ir.regulusrx.com/
Phone: 18582026300
REGULUS THERAPEUTICS INC / RGLS FAQ
What is the stock price of REGULUS THERAPEUTICS INC today?
The current stock price of RGLS is 1.35 USD. The price increased by 5.47% in the last trading session.
What is the ticker symbol for REGULUS THERAPEUTICS INC stock?
The exchange symbol of REGULUS THERAPEUTICS INC is RGLS and it is listed on the Nasdaq exchange.
On which exchange is RGLS stock listed?
RGLS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REGULUS THERAPEUTICS INC stock?
12 analysts have analysed RGLS and the average price target is 10.54 USD. This implies a price increase of 680.74% is expected in the next year compared to the current price of 1.35. Check the REGULUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REGULUS THERAPEUTICS INC worth?
REGULUS THERAPEUTICS INC (RGLS) has a market capitalization of 88.42M USD. This makes RGLS a Micro Cap stock.
How many employees does REGULUS THERAPEUTICS INC have?
REGULUS THERAPEUTICS INC (RGLS) currently has 31 employees.
What are the support and resistance levels for REGULUS THERAPEUTICS INC (RGLS) stock?
REGULUS THERAPEUTICS INC (RGLS) has a support level at 1.35 and a resistance level at 1.36. Check the full technical report for a detailed analysis of RGLS support and resistance levels.
Should I buy REGULUS THERAPEUTICS INC (RGLS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RGLS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RGLS, evaluating the profitability, health, valuation and growth aspects
- REGULUS THERAPEUTICS INC (RGLS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REGULUS THERAPEUTICS INC (RGLS) Sales and EPS estimates to see what analysts future expectations are.
- REGULUS THERAPEUTICS INC (RGLS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REGULUS THERAPEUTICS INC (RGLS) Insider and Institutional Ownership to learn about the owners and their transactions.
- REGULUS THERAPEUTICS INC (RGLS) Stock Chart to make your own analysis
- REGULUS THERAPEUTICS INC (RGLS) Latest news and press-releases to stay up to date.
Does REGULUS THERAPEUTICS INC (RGLS) stock pay dividends?
RGLS does not pay a dividend.
When does REGULUS THERAPEUTICS INC (RGLS) report earnings?
REGULUS THERAPEUTICS INC (RGLS) will report earnings on 2025-03-20, after the market close.
What is the Price/Earnings (PE) ratio of REGULUS THERAPEUTICS INC (RGLS)?
REGULUS THERAPEUTICS INC (RGLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).
What is the Short Interest ratio of REGULUS THERAPEUTICS INC (RGLS) stock?
The outstanding short interest for REGULUS THERAPEUTICS INC (RGLS) is 3.06% of its float. Check the ownership tab for more information on the RGLS short interest.
RGLS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RGLS. When comparing the yearly performance of all stocks, RGLS is a bad performer in the overall market: 76.54% of all stocks are doing better.
RGLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RGLS. RGLS has a great financial health rating, but its profitability evaluates not so good.
RGLS Financial Highlights
Over the last trailing twelve months RGLS reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 32.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.4% | ||
| ROE | -47.96% | ||
| Debt/Equity | 0 |
RGLS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to RGLS. The Buy consensus is the average rating of analysts ratings from 12 analysts.